Now let me produce the final review.

## Summary
This paper proposes an unsupervised drug-likeness prediction method that uses 2D molecular graphs rather than SMILES strings. A teacher model is pre-trained on ChEMBL with masked-atom and masked-bond modeling; a student model is distilled only on real drugs. The gap between teacher and student outputs serves as the drug-likeness score. Experiments show the method outperforms the prior unsupervised approach (a SMILES-based RNN) and eliminates a SMILES-length bias that degrades that baseline.

## Strengths
- **First 2D-graph-based unsupervised approach for drug-likeness.** All prior unsupervised work in this setting uses SMILES strings (Lee et al., 2022). The paper provides concrete evidence that this matters: Figure 5 shows the RNN baseline produces AUC below 0.5 (worse than random) for short-SMILES negatives, while the proposed method maintains robust AUC across all SMILES-length intervals on two different negative-source datasets (FDA/ZINC15, FDA/ChEMBL).
- **Directly identifies and eliminates the SMILES-length bias of the prior SOTA.** Section 5.4 constructs ten test sets stratified by negative-sample SMILES length and demonstrates that the degradation is structural in RNN (strongly correlated with length) and absent in the proposed method. This is the cleanest experimental contribution.
- **Data efficiency and generalization evidence.** Section 5.6 shows the method outperforms RNN with only 50% of training data (25% on ZINC15). Section 5.7 shows it generalizes to test molecules with low similarity to training data (FDA₂), indicating it learns distributional properties rather than memorizing.
- **Ablation study with honest discussion.** Table 2 reports that removing MBM *improves* performance on FDA/GDB17. Rather than hiding this, the paper offers a plausible explanation (MAM alone may favor GDB17's limited-heavy-atom molecules; MBM trades off specificity for generalizability). This shows the authors understand the trade-offs in their design.

## Weaknesses

### Major
- **Data leakage confounds the FDA/ChEMBL test set.** The teacher model is pre-trained on ChEMBL (line 139). One of the main test sets is FDA/ChEMBL, where negatives are ChEMBL molecules (line 174). The teacher has therefore already been exposed to the molecules it is later used to help distinguish from drugs. While the pre-training is self-supervised (not classification), this still means the teacher's representations of those negatives may be artificially distinctive compared to genuinely unseen molecules. The paper does not acknowledge this overlap or discuss its potential effect. Results on FDA/ZINC15 and FDA/GDB17 (where negatives are from different databases) are not affected, but the paper's most direct comparison involving ChEMBL-derived negatives is compromised.
- **"BondError" and "Worlddrug" are introduced but never defined.** The BondError test set is proposed as a contribution (line 139) but is never described, evaluated, or mentioned again in the paper. "Worlddrug" (line 149) is used as the positive set for the GCN baseline but is not a standard database name and receives no definition. These gaps make parts of the experimental design unreproducible and unverifiable.

### Minor
- **Novelty is overstated relative to the prior framework.** The core mechanism—teacher–student knowledge distillation gap for anomaly scoring—is inherited from GlocalKD (Ma et al., 2022), which the paper cites as "inspiration." The paper's additions (MAM/MBM pre-training tasks, 2D-graph backbone, atom-level scoring) are meaningful domain adaptations, but they operate within an existing framework. The paper calls itself "novel" and "the first attempt" without clearly delineating what is inherited vs. what is new, conflating "first application to drug-likeness" with "fundamentally new method."
- **Equation (1) contains a clear typo in the core objective.** Both terms are written as ℒ_mam when the second should be ℒ_mbm (confirmed by context on line 141: "the hyper-parameter λ₁ of ℒ_mbm"). While the intended meaning is obvious, an error in the central equation signals insufficient care in presentation.
- **Ablation reveals that MBM is not universally beneficial.** Removing MBM improves performance on FDA/GDB17 (Table 2). The paper's explanation is *post hoc* speculation based on one data point. This weakens the claim that "two carefully designed pre-training tasks" are jointly responsible for the method's success.

### Trivial
- None.

## Nice-to-Haves
- Report computational cost (training time, inference time, parameter count) vs. the RNN baseline, since the proposed model uses 12-layer Transformers pre-trained for 150K steps.
- Provide statistical significance tests (e.g., DeLong test) for AUC comparisons.
- Report exact molecule counts for each test set and clarify whether the same FDA molecules appear across multiple test splits.

## Removed Points
The following points from the inputs were reviewed and removed with brief justification:
- **Criticism that Section 5.2 (Main Results) is "missing":** The section heading exists without extracted text. Given that experimental results are distributed across Sections 5.3–5.7 with multiple figures and tables, this is most likely a parser artifact (figures/tables stripped) rather than an author omission. The paper's experimental evidence is present and accessible.
- **Criticism that RNN length-bias analysis claim is "overstated" (SMILES "can not" capture substructures):** The paper's phrasing is slightly imprecise, but the overall point—that topological structure is more naturally and robustly captured by graphs than by linear SMILES strings—is well-supported and not central to the method's validity.
- **Strength about "knowledge distillation gap as a novel unsupervised scoring mechanism":** The mechanism itself is inherited from GlocalKD. What is new is the application domain and the pre-training task design, not the core scoring paradigm. Keeping this as a strength would overstate novelty.
- **Strength claims that are generic or lack specific evidence** (e.g., "addressed an important problem," "rigorous analysis" without concrete anchor): Removed per filtering guidelines.
- **Typos/formatting nitpicks** (e.g., "SIMILES" → "SMILES," "mimics to mimic," "SMLES"): Removed per hard rule about formatting/typography artifacts. These are parser or minor author errors with no bearing on scientific evaluation.

## Novel Insights
None beyond the paper's own contributions.

## Suggestions
1. **Re-run the FDA/ChEMBL evaluation with a teacher pre-trained on a non-overlapping dataset (e.g., PubChem or ZINC).** Alternatively, identify and exclude ChEMBL test molecules from the teacher's pre-training data, and report results separately for held-out vs. seen negatives. Without this control, the strongest claim is partially confounded.
2. **Define BondError explicitly** (construction method, molecule counts, intended use) and either evaluate on it or remove the claim. Similarly, replace "Worlddrug" with the standard database name and citation.
3. **Add a clear "novelty table"** comparing the proposed method to GlocalKD along dimensions (teacher initialization, pre-training data, pre-training objectives, distillation levels, scoring function) so readers can see the delta.
4. **Fix Equation (1)** and ensure all experimental terms are defined before use.

## Score and Decision
**Score:** 5.0  
**Decision:** Reject

The paper addresses a well-motivated problem and provides convincing evidence that switching from SMILES to 2D graphs eliminates a structural bias in the prior unsupervised approach. The SMILES-length bias analysis (Figure 5) and data efficiency results (Figure 6) are genuine contributions. However, the novelty is incremental—the core teacher–student gap mechanism is inherited from prior anomaly-detection work and the additions are domain adaptations rather than fundamental advances. More critically, the evaluation is weakened by an unacknowledged training–test overlap on the FDA/ChEMBL test set and by undefined experimental components (BondError, Worlddrug) that compromise reproducibility. For a top-tier venue, the methodological advance and experimental rigor need to be stronger. The work is suitable for a more specialized molecular-informatics venue after the listed issues are addressed.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>